(Cervical Cancer) Is Keytruda Plus Platinum Chemotherapy ± Bevacizumab Effective? KEYNOTE-826 Phase 3 Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- November 15, 2021
- 2 min read
On November 11, 2021, Nicoletta Colombo and colleagues from the University of Milan-Bicocca published results in the New England Journal of Medicine from the KEYNOTE-826 Phase 3 clinical trial evaluating the efficacy and safety of pembrolizumab (Keytruda) plus platinum-based chemotherapy ± bevacizumab as first-line treatment in patients with persistent, metastatic, or recurrent cervical cancer.
This Phase 3 trial randomized patients 1:1 to pembrolizumab (200 mg every 3 weeks) plus platinum-based chemotherapy ± bevacizumab, or placebo plus platinum-based chemotherapy ± bevacizumab. The primary endpoints were progression-free survival (PFS) and overall survival (OS).
Results:
PD-L1 positive patients (CPS ≥1, N=548):
- Median PFS: Pembrolizumab 10.4 months vs. placebo 8.2 months
- 38% reduction in death risk with pembrolizumab
- 24-month OS rate: Pembrolizumab 53.0% vs. placebo 41.7%
All patients (N=617):
- Median PFS: Pembrolizumab 10.4 months vs. placebo 8.2 months
- 35% reduction in death risk with pembrolizumab
- 24-month OS rate: Pembrolizumab 50.4% vs. placebo 40.4%
PD-L1 positive patients (CPS ≥10, N=317):
- Median PFS: Pembrolizumab 10.4 months vs. placebo 8.1 months
- 42% reduction in death risk with pembrolizumab
- 24-month OS rate: Pembrolizumab 54.4% vs. placebo 44.6%
Safety:
Most common Grade 3–5 adverse events: anemia (pembrolizumab 30.3% vs. placebo 26.9%), neutropenia (pembrolizumab 12.4% vs. placebo 9.7%).
Conclusion: Based on the KEYNOTE-826 trial results, Nicoletta Colombo and colleagues concluded that pembrolizumab plus platinum-based chemotherapy ± bevacizumab as first-line treatment significantly improved PFS and OS in patients with persistent, metastatic, or recurrent cervical cancer.
Source: https://pubmed.ncbi.nlm.nih.gov/34534429/
Cervical Cancer | Immunotherapy | Keytruda | KEYNOTE-826
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4